Danielle A. Murphy
Research Subjects
Danielle A. Murphy has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Alastair Greystoke
Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom
23 shared publications - Angelo Delmonte
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
23 shared publications - Anna Tomiak
Kingston Health Sciences Centre, Kingston, Ontario, Canada
23 shared publications - Anthony Michael Joshua
Kinghorn Cancer Centre, St Vincent's Hospital Sydney Australia
23 shared publications - Bernard Doger de Spéville
Fundación Jiménez Diaz, Madrid, Spain. 5
23 shared publications - Colombe Chappey
14Pfizer, San Francisco, California
23 shared publications
Latest Publications
- Open Access
- 28 June 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Summary of the most common TRAEs (any grade in ≥30% of patients or grade ≥3 in ≥10% of patients) in the urothelial carcinoma and NSCLC cohorts
- 28 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Summary of the most common TRAEs (any grade in ≥30% of patients or grade ≥3 in ≥10% of patients) in the urothelial carcinoma and NSCLC cohorts
- Open Access
- 28 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Summary of reductions in tumor size and durations of PFS or response. A, Best percentage change from baseline in target lesions (green bars) and PFS in responding patients (gray bars) in the urothelial carcinoma cohorts.aB, DOR in responding patients and change in tumor size over time in all patients in the urothelial carcinoma cohorts. C, Best percentage change from baseline in target lesions (green bars) and PFS in responding patients (gray bars) in the NSCLC cohorts. TMB high represents >10 mut/Mb. In urothelial carcinoma cohorts, PD-L1–positive status was defined using an algorithm that combines assessments of PD-L1 staining on tumor and immune cells, which were scored by pathologists (30); in NSCLC cohorts, PD-L1–positive status was defined as PD-L1 expression on ≥1% of tumor cells. PD-L1, programmed death-ligand 1; TMB, tumor mutational burden; FGFR, fibroblast growth factor receptor.aTwo patients with no postbaseline tumor assessments who were receiving avelumab 1,200 mg were excluded.
- 28 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Summary of reductions in tumor size and durations of PFS or response. A, Best percentage change from baseline in target lesions (green bars) and PFS in responding patients (gray bars) in the urothelial carcinoma cohorts.aB, DOR in responding patients and change in tumor size over time in all patients in the urothelial carcinoma cohorts. C, Best percentage change from baseline in target lesions (green bars) and PFS in responding patients (gray bars) in the NSCLC cohorts. TMB high represents >10 mut/Mb. In urothelial carcinoma cohorts, PD-L1–positive status was defined using an algorithm that combines assessments of PD-L1 staining on tumor and immune cells, which were scored by pathologists (30); in NSCLC cohorts, PD-L1–positive status was defined as PD-L1 expression on ≥1% of tumor cells. PD-L1, programmed death-ligand 1; TMB, tumor mutational burden; FGFR, fibroblast growth factor receptor.aTwo patients with no postbaseline tumor assessments who were receiving avelumab 1,200 mg were excluded.
- Open Access
- 28 June 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Summary of the most common TRAEs (any grade in ≥30% of patients or grade ≥3 in ≥10% of patients) in the urothelial carcinoma and NSCLC cohorts
- 28 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Summary of the most common TRAEs (any grade in ≥30% of patients or grade ≥3 in ≥10% of patients) in the urothelial carcinoma and NSCLC cohorts
- Open Access
- 28 June 2024
- Published by American Association for Cancer Research (AACR)
TABLE 3 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Summary of efficacy in the urothelial carcinoma and NSCLC cohorts
- 28 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 3 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Summary of efficacy in the urothelial carcinoma and NSCLC cohorts